Editas Medicine pads runway with $50M upfront from Vertex for Cas9 license
As Editas Medicine attempts to catch up to the historic approval of Vertex Pharmaceuticals and CRISPR Therapeutics’ gene-edited sickle cell treatment, the biotech will get $50 million in cash from the pack’s leader.
Vertex will dole out the upfront payment for a non-exclusive license to Editas’ Cas9 gene editing technology as it relates to ex vivo gene editing medicines that target the BCL11A gene for sickle cell disease and the blood disorder beta thalassemia, the companies said Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
